Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.54 |
| ▸ | AXL | P30530 | 5/20 | 0.50 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.50 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2882894 | 0.90 | CYP2D6 (0.59) | CYP2D6CYP2C9AXLAAK1PAK1 | |
| SCHEMBL3506675 | 0.86 | AXL (0.58) | CYP2C9AXLAAK1PAK1 | |
| SCHEMBL294277 | 0.86 | CYP2C9 (0.67) | CYP2D6CYP2C9AXLAAK1PAK1 | |
| SCHEMBL3507602 | 0.85 | CYP2C9 (0.45) | CYP2D6CYP2C9AXLAAK1PAK1 | |
| SCHEMBL298234 | 0.85 | CYP2C9 (0.67) | CYP2D6CYP2C9CYP2C19BRAF | |
| SCHEMBL2357395 | 0.84 | BRAF (0.53) | CYP2C9AXLPAK1CYP2C19BRAF | |
| SCHEMBL15667584 | 0.84 | CYP2D6 (0.57) | CYP2D6CYP2C9AXLAAK1PAK1 | |
| SCHEMBL3506503 | 0.83 | DYRK1A (0.53) | CYP2C9AXLAAK1PAK1 | |
| SCHEMBL15667586 | 0.82 | CYP2D6 (0.64) | CYP2D6CYP2C9AAK1CYP2C19BRAF | |
| SCHEMBL3705469 | 0.82 | CYP3A4 (0.52) | CYP2D6CYP2C9AXLAAK1PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010129567-A1 | PYRROLO [2, 3. B] PYRIDINES WHICH INHIBIT RAF PROTEIN KINASE | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | claimed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | claimed |
| US-20120245174-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-09-27 | — | — | US | disclosed |
| US-8198273-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| WO-2010129567-A1 | PYRROLO [2, 3. B] PYRIDINES WHICH INHIBIT RAF PROTEIN KINASE | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | CYP2D6 3025/4885CYP2C9 2176/4885AXL 470/4885 |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, ARAF, RAF1 | CYP2D6 2083/4885CYP2C9 2237/4885AXL 97/4885 |
| US-20120245174-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, ARAF, RAF1 | CYP2D6 2083/4885CYP2C9 2237/4885AXL 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.